-
-
-
-
-
-
-
Stifel on Travere Therapeutics (TVTX): 'FSGS Increases Risk of CRL, Though Delay/Approval Still Possible'
-
-
-
-
-
-
-
Stifel Reiterates Hold Rating on Travere Therapeutics (TVTX)
-
-
-
-
-
-
-
Travere Therapeutics Reports Second Quarter 2025 Financial Results
-
-
-
-
-
-
-
Travere Therapeutics Reports First Quarter 2025 Financial Results
-
-
-
-
-
-
-
Travere Therapeutics (TVTX) PT Raised to $12 at Piper Sandler
-
-
-
-
-
-
-
Ligand Reports Third Quarter 2023 Financial Results
-
-
-
-
-
-
-
Travere Therapeutics Reports Third Quarter 2022 Financial Results
-
14,982 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

